Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

被引：0

作者：

Lisa A. Carey

Delphine Loirat

Kevin Punie

Aditya Bardia

Véronique Diéras

Florence Dalenc

Jennifer R. Diamond

Christel Fontaine

Grace Wang

Hope S. Rugo

Sara A. Hurvitz

Kevin Kalinsky

Joyce O’Shaughnessy

Sibylle Loibl

Luca Gianni

Martine Piccart

Yanni Zhu

Rosemary Delaney

See Phan

Javier Cortés

机构：

[1] University of North Carolina Lineberger Comprehensive Cancer Center,Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute

[2] Medical Oncology Department and D3i,Department of Hematology/Oncology

[3] Institut Curie,Department of Medical Oncology

[4] University Hospitals Leuven,Division of Medical Oncology, Department of Medicine

[5] Massachusetts General Hospital Cancer Center,Medical Oncology Department

[6] Harvard Medical School,Department of Medicine

[7] Centre Eugène Marquis,Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine

[8] Institut Claudius Regaud,Department of Medicine and Research

[9] IUCT-Oncopole,Medical Oncology

[10] University of Colorado Anschutz Medical Campus,Medical Oncology Department

[11] Oncologisch Centrum,Department of Biostatistics

[12] UZ Brussel,Department of Clinical Research

[13] Miami Cancer Institute,Department of Clinical Development

[14] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,International Breast Cancer Center, Quirón Group, Barcelona

[15] University of California,undefined

[16] Los Angeles,undefined

[17] Jonsson Comprehensive Cancer Center,undefined

[18] Winship Cancer Institute,undefined

[19] Emory University,undefined

[20] Baylor University Medical Center,undefined

[21] Texas Oncology,undefined

[22] US Oncology,undefined

[23] Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus,undefined

[24] Gianni Bonadonna Foundation,undefined

[25] Institut Jules Bordet and l’Université Libre de Bruxelles,undefined

[26] Gilead Sciences,undefined

[27] Inc,undefined

[28] Gilead Sciences,undefined

[29] Inc,undefined

[30] Gilead Sciences Inc,undefined

[31] Universidad Europea de Madrid,undefined

[32] Faculty of Biomedical and Health Sciences,undefined

[33] Department of Medicine,undefined

[34] Madrid,undefined

[35] Vall d´Hebron Institute of Oncology (VHIO),undefined

来源：

npj Breast Cancer | / 8卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

引用

共 46 条

[1]

Kohler BA(2015)Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state J. Natl. Cancer Inst. 107 djv048-882

[2]

Plasilova ML(2016)Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database Medicine 95 e4614-804

[3]

Newman LA(2015)The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer Ann. Surg. Oncol. 22 874-1649

[4]

Reis-Filho JS(2012)Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up Breast Cancer Res. Treat. 136 795-52

[5]

Morrow M(2020)5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann. Oncol. 31 1623-271

[6]

Carey LA(2019)Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review Breast Cancer Res. 21 43-1531

[7]

King TA(2019)Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01) Cancer Res. Treat. 51 261-1281

[8]

Malorni L(2010)Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer Breast Cancer Res. Treat. 121 1525-5472

[9]

Cardoso F(2016)Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy Ann. Oncol. 27 1275-S96

[10]

Li CH(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J. Clin. Oncol. 26 5463-95

← 1 2 3 4 5 →